Sernova Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Jonathan M. Rigby

Chief executive officer

CA$3.4m

Total compensation

CEO salary percentage	6.1%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	4.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jonathan M. Rigby's remuneration changed compared to Sernova's earnings?
Date	Total Compensation	Salary	Company Earnings
Oct 31 2024	CA$3m	CA$211k	-CA$32m

Compensation vs Market: Jonathan M.'s total compensation ($USD2.40M) is above average for companies of similar size in the US market ($USD638.32K).

Compensation vs Earnings: Insufficient data to compare Jonathan M.'s compensation with company performance.

CEO

Jonathan M. Rigby (56 yo)

less than a year

Tenure

CA$3,432,127

Compensation

Mr. Jonathan M. N. Rigby, M.B.A., had been Executive Chairman of Sernova Corp. since July 15, 2024 until 2025 and serves as its Director since May 28, 2024 and CEO since August 2024. He is Chairman and Chi...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jonathan M. Rigby	CEO & Director	less than a year	CA$3.43m	no data
James Parsons	Chief Financial Officer	less than a year	CA$1.38m	0.12% $ 56.6k
Frank Shannon	Senior VP of Clinical Development and Regulatory Affairs	less than a year	CA$335.83k	no data
Modestus Obochi	Chief Business Officer	1.4yrs	CA$499.49k	0.015% $ 7.4k
David Burke	Vice President of Investor Relations	1.1yrs	no data	no data
Marylyn Rigby	Chief Communications Officer	less than a year	no data	no data

0.4yrs

Average Tenure

Experienced Management: SEOV.F's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Jonathan M. Rigby	CEO & Director	less than a year	CA$3.43m	no data
R. Ross Haghighat	Chairman & Observer	less than a year	no data	no data
Norman C. Wong	Member of Scientific Advisory Board	18.6yrs	no data	no data
Jannette Dufour	Member of Scientific Advisory Board	18.5yrs	no data	no data
George King	Member of Scientific Advisory Board	no data	no data	no data
Clive Patience	Member of Scientific Advisory Board	18.2yrs	no data	no data
Steven Paraskevas	Member of Scientific Advisory Board	14.2yrs	no data	no data
Bernd Muehlenweg	Director	less than a year	CA$114.00k	no data
David Lillicrap	Member of Scientific Advisory Board	6.1yrs	no data	no data
Anke Schulte	Member of Global Advisory Board	4.6yrs	no data	no data
Stephen Sangha	Independent Director	1.8yrs	CA$126.89k	3.98% $ 1.9m
Sam Wiseman	Member of Scientific Advisory Board	3.8yrs	no data	no data

4.6yrs

Average Tenure

58yo

Average Age

Experienced Board: SEOV.F's board of directors are considered experienced (4.6 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/07 00:12
End of Day Share Price	2025/02/07 00:00
Earnings	2024/10/31
Annual Earnings	2024/10/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sernova Corp. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Christian Orquera	First Berlin Equity Research GmbH
Joseph Pantginis	H.C. Wainwright & Co.
Chelsea Stellick	iA Capital Markets

Sernova Management

Management criteria checks 1/4

Key information

Recent management updates

Sernova Biotherapeutics Announces Appointment of Ross Haghighat as Chair of the Board

Sernova Corp. Appoints James Parsons as Chief Financial Officer

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

Sernova Corp., Annual General Meeting, Apr 30, 2024

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

Recent updates

Sernova Biotherapeutics Submits IND Application for its Cell Pouch Bio-Hybrid Organ with Autograft Thyroid Cells in Patients with Hypothyroidism

Sernova Biotherapeutics Announces Appointment of Ross Haghighat as Chair of the Board

Sernova Corp. Appoints James Parsons as Chief Financial Officer

Sernova Corp. Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Sernova Corp. announced that it has received CAD 5.2 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

Sernova Corp., Annual General Meeting, Apr 30, 2024

Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress

Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting

Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™? at American Diabetes Association 83rd Scientific Sessions

Sernova Corp. Announces Executive Changes

Sernova Corp., Annual General Meeting, Apr 27, 2023

Sernova Announces Advancements with Its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Sernova Corp. Announces Executive Changes

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of Its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

Sernova Corp. Appoints Daniel Mahony, Ph.D. to Its Board of Directors, Effective from September 30, 2022

Sernova Corp. Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System Tm at American Diabetes Association 82nd Scientific Sessions 2022

Sernova Corp.(TSXV:SVA) dropped from S&P/TSX Venture Composite Index

Sernova Corp. announced that it has received CAD 20.323499 million in funding from Evotec SE

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation At American Diabetes Association 82Nd Scientific Sessions 2022

Sernova Corp., Annual General Meeting, Apr 28, 2022

Sernova Corp. Announces Publication of A Peer Reviewed Preclinical Study Demonstrating Positive Results of A Novel Cell Pouch System Cell Therapy

Sernova Corp. Provides Progress Update on Its Phase 1/2 T1d Clinical Trial

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference

Sernova Corp. has completed a Composite Units Offering in the amount of CAD 20.04 million.

Sernova Corp Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System Clinical Trial and Recommendation for Protocol Continuation

Sernova Corp. Announces Collaboration Agreements with Multiple Pharmaceutical Industry Leaders

Sernova Corp. Provides Clinical Update on U.S. Phase I/II Cell Pouch Trial for Type 1 Diabetes

Sernova Corp. announced that it has received CAD 3.6655 million in funding

Sernova Corp. announced that it expects to receive CAD 3 million in funding

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources